30th Jun 2025 10:29
(Alliance News) - Hikma Pharmaceuticals PLC has pledged to invest USD1 billion by 2030 to further expand its US manufacturing and R&D capabilities.
In a statement on Saturday, the London-based pharmaceutical company said the investment will help develop, produce and deliver a broad range of medicines needed by the US healthcare system.
The investment will increase the volume of medicines Hikma develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey.
Hikma has operated in the US since 1991 and has spent more than USD4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines, it said in a statement.
Shares in Hikma were up 0.1% at 2,028.00 pence each in London on Monday morning.
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Hikma Pharmaceuticals